Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Deffered Revenue (2023 - 2025)

BridgeBio Pharma (BBIO) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 23.49% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, down 23.49% year-over-year, with the annual reading at $13.1 million for FY2025, 23.49% down from the prior year.
  • Non-Current Deffered Revenue hit $13.1 million in Q4 2025 for BridgeBio Pharma, roughly flat from $13.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $19.9 million in Q1 2024 to a low of $3.7 million in Q4 2023.
  • Historically, Non-Current Deffered Revenue has averaged $15.0 million across 3 years, with a median of $17.0 million in 2024.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 358.68% in 2024 and later dropped 29.51% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $3.7 million in 2023, then skyrocketed by 358.68% to $17.1 million in 2024, then fell by 23.49% to $13.1 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for BBIO at $13.1 million in Q4 2025, $13.1 million in Q3 2025, and $14.7 million in Q2 2025.